IP Library › Granted Patent US 10,245,327
Granted Patent B2
US 10,245,327 · App. 15/374,805 · Granted Apr 2, 2019

Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GemVax & KAEL Co., Ltd.
A61K49/0056A23L33/175A23L33/18A61K9/0019A61K47/64A61K49/0043C07K7/08C07K14/00A23V2002/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,245,327
App. No.
15/374,805
Granted
Apr 2, 2019
Kind
B2
Abstract

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Claims (34)

1. A conjugate having cell penetrating activity, wherein the conjugate comprises a cell penetrating carrier peptide and an active ingredient, the carrier peptide is 11 amino acids in length and consists of the amino acid sequence of SEQ ID NO:139, and wherein the carrier peptide increases the cell penetration of the active ingredient.

2. The conjugate according to claim 1 , wherein the active ingredient is a protein, nucleic acid, peptide, lipid, mineral, sugar, nano-particle, contrast agent, or drug.

3. The conjugate according to claim 2 , wherein the active ingredient is a protein or a peptide.

4. The conjugate according to claim 3 , wherein the active ingredient is a cytokine, antibody, fragment of antibody, therapeutic enzyme, soluble receptor or ligand.

5. The conjugate according to claim 2 , wherein the contrast agent is selected from the group consisting of radiopaque contrast agent, paramagnetic contrast agent, superparamagnetic contrast agent and computed tomography (CTS contrast agent.

6. The conjugate according to claim 2 , wherein the contrast agent comprises iron.

7. The conjugate according to claim 6 , wherein the contrast agent is a ferrocene carboxylate.

8. The conjugate according to claim 1 , wherein the carrier peptide is bonded to the active ingredient via a covalent bond and optionally mediated by a linker.

9. The conjugate according to claim 1 , wherein the carrier peptide is bonded to the active ingredient via a non-covalent bond.

10. A contrast agent comprising the conjugate of claim 1 .

11. A cell comprising the contrast agent according to claim 10 .

12. The cell according to claim 11 , wherein the host cell is a stem cell.

13. A composition comprising the conjugate according to claim 1 as an active ingredient wherein the composition is selected from a pharmaceutical composition, a cosmetic composition, and a health food composition.

14. The composition according to claim 13 , wherein the composition is a pharmaceutical composition.

15. The composition according to claim 13 , wherein the composition is a cosmetic composition.

16. The composition according to claim 13 , wherein the composition is a health food composition.

17. A cell penetrating carrier peptide that is 11 amino acids in length and consists of the amino acid sequence of SEQ ID NO: 139.

18. A conjugate having cell penetrating activity, wherein the conjugate comprises a cell penetrating carrier peptide and an active ingredient, the carrier peptide is 12 amino acids in length and consists of the amino acid sequence of SEQ ID NO:130, and wherein the carrier peptide increases the cell penetration of the active ingredient.

19. The conjugate according to claim 18 , wherein the active ingredient is a protein, nucleic acid, peptide, lipid, mineral, sugar, nano-particle, contrast agent, or drug.

20. The conjugate according to claim 19 , wherein the active ingredient is a protein or a peptide.

21. The conjugate according to claim 20 , wherein the active ingredient is a cytokine, antibody, fragment of antibody, therapeutic enzyme, soluble receptor or ligand.

22. The conjugate according to claim 19 , wherein the contrast agent is selected from the group consisting of radiopaque contrast agent, paramagnetic contrast agent, superparamagnetic contrast agent and computed tomography (CT) contrast agent.

23. The conjugate according to claim 19 , wherein the contrast agent comprises iron.

24. The conjugate according to claim 23 , wherein the contrast agent is a ferrocene carboxylate.

25. The conjugate according to claim 18 , wherein the carrier peptide is bonded to the active ingredient via a covalent bond and optionally mediated by a linker.

26. The conjugate according to claim 18 , wherein the carrier peptide is bonded to the active ingredient via a non-covalent bond.

27. A contrast agent comprising the conjugate of claim 18 .

28. A cell comprising the contrast agent according to claim 27 .

29. The cell according to claim 28 , wherein the host cell is a stem cell.

30. A composition comprising the conjugate according to claim 18 as an active ingredient; wherein the composition is selected from a pharmaceutical composition, a cosmetic composition, and a health food composition.

31. The composition according to claim 30 , wherein the composition is a pharmaceutical composition.

32. The composition according to claim 30 , wherein the composition is a cosmetic composition.

33. The composition according to claim 30 , wherein the composition is a health food composition.

34. A cell penetrating carrier peptide that is 12 amino acids in length and consists of the amino acid sequence of SEQ ID NO: 130.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 040829/0956 →
Priority Claims (5)
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104173 · Sep 19, 2012 · national
KR 10-2012-0109207 · Sep 28, 2012 · national
KR 10-2012-0109216 · Sep 28, 2012 · national
KR 10-2013-0017046 · Feb 18, 2013 · national
Continuity (2)
Division 14429644
Related Publication 20170112942A1 · Apr 27, 2017